Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Receivables (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Change in Receivables for 3 consecutive years, with $22.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 25.89% to $22.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $39.3 million, a 5.84% increase, with the full-year FY2025 number at $39.3 million, up 5.84% from a year prior.
  • Change in Receivables was $22.3 million for Q4 2025 at Phathom Pharmaceuticals, up from $4.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $22.3 million in Q4 2025 to a low of -$2.4 million in Q1 2025.
  • A 3-year average of $8.7 million and a median of $7.0 million in 2024 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 984.0% in 2024, then plummeted 208.47% in 2025.
  • Phathom Pharmaceuticals' Change in Receivables stood at $1.6 million in 2023, then soared by 984.0% to $17.7 million in 2024, then grew by 25.89% to $22.3 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Change in Receivables are $22.3 million (Q4 2025), $4.5 million (Q3 2025), and $14.9 million (Q2 2025).